Restless legs syndrome
also known as RLS, Willis-Ekbom disease
Medically reviewed by the Shrinkopedia editorial team, led by Shariq Refai, MD, MBA, FAPA.
11 min read · 2,473 words
- Medically reviewed . Reviewed by a board-certified psychiatrist before publication.
- Sourced from primary literature . DSM-5-TR, NICE, the American Psychiatric Association, the NIMH, Cochrane, peer-reviewed research.
- Dated and kept current . Every entry shows when it was published, reviewed, and last updated.
- Honest about uncertainty . Each entry carries an evidence-strength rating and a "what we know and what we don't" section.
- Independent . No advertising, no affiliate revenue, no sponsored content.
Restless legs syndrome is a common neurological disorder characterized by an uncomfortable urge to move the legs, most often felt in the evening and at night, that is relieved by movement. It has significant effects on sleep, mood, and quality of life. Estimated prevalence is 5-10 percent of adults, with a subset having clinically significant symptoms. Iron deficiency is a common driver, and iron replacement is often the highest-leverage single intervention. When medication is needed, alpha-2-delta ligands (gabapentin, gabapentin enacarbil, pregabalin) are typically first-line. Dopamine agonists were historically first-line but their use has been substantially reduced due to augmentation (paradoxical worsening with long-term use). Iron infusion is now more widely used for symptomatic patients with low-normal ferritin.
What research says
Prevalence. 5-10 percent of adults have some RLS symptoms; 1-3 percent have clinically significant symptoms. Higher in women than men. Increases with age.
Course. Chronic and often progressive. Can wax and wane. Often triggered or worsened by specific circumstances (pregnancy, iron loss, medications).
Comorbidity. - Insomnia disorder (from RLS-related sleep disruption) - Depression and anxiety - Iron deficiency - Peripheral neuropathy - ESRD (very common) - Pregnancy (transient trigger) - Parkinson's disease (associated but not a Parkinson's variant)
Treatment evidence. - Iron replacement: strong evidence when ferritin is low. IV iron increasingly used. - Alpha-2-delta ligands (gabapentin, gabapentin enacarbil, pregabalin): current first-line pharmacological treatment. Good evidence. - Dopamine agonists (pramipexole, ropinirole, rotigotine patch): previously first-line. Now second-line due to augmentation concerns. - Opioids (low-dose): for refractory cases. Reserved due to abuse potential. - Behavioral approaches: leg stretching, exercise, sleep hygiene, avoiding triggers.
Augmentation. Long-term dopamine agonist use produces paradoxical worsening in a substantial percentage of patients (some estimates 40-70 percent over years). Symptoms occur earlier in the day, spread to arms, become more intense, and require increasing doses. Recognized and articulated by Garcia-Borreguero and colleagues. Has driven the shift away from dopamine agonists as first-line.
Questions people ask
Is RLS a real condition?
Yes. Well-defined neurological disorder with characteristic features, biological mechanism (iron and dopamine), and effective treatments.
What causes RLS?
The main mechanism involves brain iron and dopamine. Iron is a cofactor for dopamine synthesis; brain iron deficiency reduces dopamine availability in ways that produce RLS symptoms. Genetic factors also contribute.
Does iron really matter?
Yes, substantially. Iron deficiency (or low-normal iron) drives RLS in many patients. Iron replacement is often the most effective single intervention. Consider iron testing (ferritin ≤75 ng/mL is often clinically significant, even though standard "deficiency" thresholds are lower).
Should I use a dopamine agonist for RLS?
No longer first-line. Long-term use of pramipexole or ropinirole produces augmentation (paradoxical worsening) in a substantial percentage of patients. Current guidelines favor alpha-2-delta ligands (gabapentin, pregabalin) as first-line.
What is augmentation?
Paradoxical worsening of RLS symptoms with long-term dopamine agonist use. Symptoms occur earlier in the day, spread to arms, become more intense, and require increasing doses. Real and increasingly recognized problem.
Does RLS mean I have Parkinson's?
No. RLS is not a Parkinson's variant. Some patients have both conditions, but RLS alone does not indicate Parkinson's risk.
Is RLS hereditary?
Substantially. Family history is very common. Several genetic variants identified.
Can pregnancy cause RLS?
Yes. RLS is common in pregnancy, particularly in the third trimester. Often resolves postpartum. Iron replacement is often helpful; medication selection during pregnancy requires care.
What if I have RLS during pregnancy?
Address iron status. Non-pharmacological approaches first. If medication is needed, discuss with your obstetric and neurology teams. Some options are safer than others in pregnancy.
Does RLS affect mood?
Yes. Sleep disruption from RLS produces mood effects. Depression is a common comorbidity. Treating RLS often improves mood substantially.
Which medications worsen RLS?
First-generation antihistamines (diphenhydramine), dopamine antagonists (many antipsychotics), some antidepressants (particularly SSRIs and SNRIs in some patients), some antiemetics. If your RLS worsened after starting a medication, review with your prescribing clinician.
Does exercise help?
Moderate regular exercise typically helps. Very intense exercise late in the day may worsen symptoms in some patients.
What RLS is
RLS is diagnosed by the International Restless Legs Syndrome Study Group (IRLSSG) criteria, which require all five of the following:
1. An urge to move the legs, usually accompanied by or thought to be caused by uncomfortable and unpleasant sensations in the legs 2. Begins or worsens during periods of rest or inactivity (lying, sitting) 3. Partially or totally relieved by movement (walking, stretching, at least as long as the activity continues) 4. Worse in the evening or night than during the day, or occurs only in the evening or night 5. Not solely accounted for by another medical or behavioral condition (leg cramps, positional discomfort, myalgia, venous stasis, leg edema, arthritis, or habitual foot tapping)
Severity classification uses the International RLS Rating Scale (IRLS).
Frequency: - Intermittent: symptoms present less than 2 times per week - Chronic-persistent: symptoms present at least 2 times per week
RLS is distinct from periodic limb movement disorder (PLMD), though the two often coexist. PLMD involves repetitive limb movements during sleep, detected on polysomnography, with associated sleep disruption.
What it feels like
The sensations of RLS are notoriously difficult to describe. Common descriptions:
- Creeping, crawling, itching sensations in the legs
- Pins and needles
- Aching or throbbing
- Buzzing or vibrating
- Feeling like something is "under the skin"
- Pulling sensation
- Just uncomfortable in a way that's hard to name
The urge to move is the core feature. Not just discomfort but a compelling drive to move the legs to reduce the discomfort. Movement provides temporary relief that lasts as long as the movement continues.
Timing pattern is essential: - Worse when at rest, better with movement - Worse in evening and night, often absent during the day (or milder) - Interferes with falling asleep and returning to sleep
Sleep impact is substantial: - Difficulty falling asleep because of restlessness at bedtime - Awakenings during the night with urge to move - Reduced total sleep time - Poor sleep quality - Daytime consequences: fatigue, mood effects, cognitive effects
Location. Most commonly the legs (calves, thighs, feet), but can involve arms and less commonly other body regions.
Emotional impact. RLS is often deeply distressing, particularly when severe. Sleep disruption compounds mood effects. Depression and anxiety are common downstream consequences and often improve with adequate RLS treatment.
Differential diagnosis
Nocturnal leg cramps. Sudden painful contractions. Relieved by stretching. Different pattern from RLS.
Peripheral neuropathy. Can produce leg discomfort. Distinguishable by physical exam, neurological testing, and the absence of the RLS urge-to-move pattern.
Venous insufficiency. Aching, swelling, worse with prolonged standing. Distinguishable by pattern.
Akathisia. Restlessness produced by antipsychotic and other medications. Distinguishable by history of medication exposure and pattern.
Peripheral arterial disease. Claudication with exercise, relieved by rest. Opposite pattern from RLS.
Positional discomfort. Relieved by position change but doesn't have the specific RLS quality.
Anxiety and akathisia-like presentations. Some anxiety presentations include leg restlessness. RLS-specific criteria distinguish.
Fibromyalgia. Widespread pain that may include legs but different pattern.
Musculoskeletal conditions. Arthritis, tendon problems, muscle strains all can produce leg discomfort but not the RLS pattern.
Why it happens
Iron and dopamine. The central pathophysiology involves iron and brain dopamine metabolism. Brain iron is a cofactor for dopamine synthesis. Low brain iron reduces dopamine availability at appropriate times, which is thought to drive RLS symptoms. This is a key insight guiding modern treatment.
Circadian pattern. The evening/night worsening reflects circadian variation in brain dopamine.
Genetics. Substantial heritability. Several risk variants identified through genetic studies (MEIS1, BTBD9, MAP2K5). Family history is common.
Iron deficiency. Systemic iron deficiency (low ferritin) drives RLS in many patients. Ferritin ≤75 ng/mL is often considered clinically significant for RLS, even though standard "normal" ferritin ranges have wider thresholds.
Pregnancy. Common trigger. Related to iron and hormonal changes.
End-stage renal disease. Very common in dialysis patients.
Neuropathy. Peripheral neuropathy may coexist and complicate treatment.
Medications that worsen RLS. Antihistamines (particularly first-generation, like diphenhydramine), dopamine antagonists (including many antipsychotics), some antiemetics, some antidepressants (particularly SSRIs and SNRIs in some patients).
Alcohol, caffeine, nicotine. May worsen symptoms.
Assessment
Clinical interview with attention to the IRLSSG criteria. Distinguishing RLS from mimics is often possible from history alone.
Laboratory workup. - Ferritin: essential. Iron replacement is one of the most effective RLS treatments. - Iron studies (serum iron, TIBC, transferrin saturation): completes iron assessment - CBC - Kidney function - Blood glucose (if neuropathy suspected) - B12 - TSH
Some centers use CSF ferritin measurement in complex cases (brain iron may be low even when systemic iron seems normal).
Sleep study if PLMD or other sleep disorder is suspected.
Assessment for aggravating factors: - Medications that worsen RLS - Alcohol, caffeine, nicotine use - Pregnancy - Iron loss (menstrual bleeding, GI bleeding) - Comorbid conditions
Treatment
Non-pharmacological approaches are always appropriate and are sufficient for many patients with mild-to-moderate symptoms.
- Regular exercise (moderate intensity)
- Sleep hygiene
- Avoiding known triggers (alcohol, caffeine, nicotine near bedtime)
- Leg stretching and massage
- Hot or cold compresses (individual preference)
- Compression stockings for some
- Reviewing medications for RLS aggravators
- Iron-rich diet
Iron replacement. Consider when ferritin is ≤75 ng/mL (higher than the standard "deficient" cutoff).
- Oral iron: ferrous sulfate 325 mg or equivalent, once daily or every other day (recent evidence supports every-other-day dosing for better absorption). May take months to raise ferritin adequately.
- IV iron: for patients who can't tolerate oral iron, have poor absorption, or need faster response. Increasingly used first-line for symptomatic patients with low-normal ferritin. Ferric carboxymaltose is common. Iron isomaltoside is another option.
- Recheck ferritin at 8-12 weeks. Iron replacement can produce dramatic improvement.
Alpha-2-delta ligands (current first-line pharmacological treatment).
- Gabapentin enacarbil (Horizant): FDA-approved specifically for RLS. 600 mg daily.
- Gabapentin: 300-1800 mg divided doses, or single dose at bedtime for evening/night symptoms. Off-label but widely used.
- Pregabalin (Lyrica): 150-450 mg daily. Off-label.
Advantages: no augmentation, effective, generally well-tolerated. Common side effects: sedation, dizziness, edema.
Dopamine agonists (now second-line due to augmentation concerns).
- Pramipexole (Mirapex): 0.125-0.5 mg 2 hours before bedtime
- Ropinirole (Requip): 0.25-4 mg 1-3 hours before bedtime
- Rotigotine patch (Neupro): 1-3 mg/24 hours
Advantages: effective initially. Disadvantages: augmentation with long-term use, impulse control disorders (particularly with pramipexole and ropinirole), rebound worsening on missed doses.
If used, keep doses low, monitor for augmentation, and consider transition to alpha-2-delta ligands if augmentation develops.
Refractory cases:
- Low-dose opioids: methadone, oxycodone. Effective but reserved due to abuse potential. Careful patient selection and monitoring.
- Combination approaches: alpha-2-delta ligand plus dopamine agonist (with careful monitoring)
- IV iron even if ferritin is not clearly low
- Referral to specialty sleep or movement disorders center
Special populations.
- Pregnancy: preferred treatment is iron replacement, leg movement, and avoidance of aggravators. Some medications (gabapentin, opioids) are used with caution in pregnancy. Symptoms often resolve postpartum.
- ESRD: RLS is very common. Iron replacement, alpha-2-delta ligands, dopamine agonists all used. Renal dosing considerations.
- Elderly: side-effect sensitivity considerations. Falls risk with sedating medications.
Comorbid conditions.
- Iron deficiency: address as above
- Depression: treatment often improves; some antidepressants may worsen RLS
- Sleep disorders: treat all present
- Peripheral neuropathy: address when present
Cultural and structural considerations
Diagnostic delay is common. RLS is often dismissed or misattributed.
Access to specialists (sleep medicine, neurology) varies.
IV iron access varies. Not universally available in primary care settings.
Cost of medications varies. Generic gabapentin is inexpensive; brand-name alpha-2-delta ligands and dopamine agonists are expensive.
Pregnancy considerations for RLS remain undertaught. Pregnant patients with severe RLS deserve appropriate management.
Living with RLS
For the person. Iron replacement often produces substantial improvement and is worth pursuing when applicable. Non-pharmacological approaches provide meaningful relief for many. When pharmacological treatment is needed, starting with alpha-2-delta ligands rather than dopamine agonists avoids augmentation. Regular follow-up for symptom monitoring matters.
For family or partners. RLS-related sleep disruption affects bed partners too. Understanding the condition helps. Supporting appropriate treatment access matters.
Sources
- Allen RP, Picchietti DL, Garcia-Borreguero D, et al. Restless legs syndrome/Willis-Ekbom disease diagnostic criteria: updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria. Sleep Medicine. 2014;15(8):860-873.
- Trotti LM. Restless Legs Syndrome. Continuum (Minneap Minn). 2017;23(4, Sleep Neurology):1005-1016.
- Silber MH, Buchfuhrer MJ, Earley CJ, Koo BB, Manconi M, Winkelman JW. The management of restless legs syndrome: an updated algorithm. Mayo Clinic Proceedings. 2021;96(7):1921-1937.
- Aurora RN, Kristo DA, Bista SR, et al. The treatment of restless legs syndrome and periodic limb movement disorder in adults - an update for 2012: practice parameters with an evidence-based systematic review and meta-analyses: an American Academy of Sleep Medicine Clinical Practice Guideline. Sleep. 2012;35(8):1039-1062.
- Winkelman JW, Armstrong MJ, Allen RP, et al. Practice guideline summary: treatment of restless legs syndrome in adults: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2016;87(24):2585-2593.
- Allen RP, Chen C, Garcia-Borreguero D, et al. Comparison of pregabalin with pramipexole for restless legs syndrome. New England Journal of Medicine. 2014;370(7):621-631.
- Trenkwalder C, Winkelmann J, Oertel W, et al. Ferric carboxymaltose in patients with restless legs syndrome and iron deficiency: a randomized, double-blind study. Movement Disorders. 2017;32(10):1478-1482.
- Garcia-Borreguero D, Silber MH, Winkelman JW, et al. Guidelines for the first-line treatment of restless legs syndrome/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation. Sleep Medicine. 2016;21:1-11.
- Earley CJ, Connor J, Garcia-Borreguero D, et al. Altered brain iron homeostasis and dopaminergic function in restless legs syndrome. Sleep Medicine. 2014;15(11):1288-1301.
- Winkelmann J, Schormair B, Xiong L, Dion PA, Rye DB, Rouleau GA. Genetics of restless legs syndrome. Sleep Medicine. 2017;31:18-22.
- International Restless Legs Syndrome Study Group: irlssg.org.
Read how Shrinkopedia builds and reviews its content.
How to cite this page
- Short
Restless legs syndrome. Shrinkopedia, medically reviewed by Shariq Refai, MD, MBA. https://shrinkopedia.com/conditions/restless-legs-syndrome/- APA
Shrinkopedia. (2026, July 13). Restless legs syndrome. Medically reviewed by Shariq Refai, MD, MBA. https://shrinkopedia.com/conditions/restless-legs-syndrome/- MLA
"Restless legs syndrome." Shrinkopedia, 13 July 2026, https://shrinkopedia.com/conditions/restless-legs-syndrome/.
Click a citation to select it.
See where this fits in the Atlas: how your mind works →
When evaluation may help
Reading a reference is not the same thing as being evaluated. If what you just read matches your own experience closely, if the pattern has been getting in the way of work, relationships, or daily life, or if you have questions that only a clinician who knows your situation can answer, a professional evaluation is a reasonable next step. Reading forward without seeking evaluation is also a reasonable choice for many people. There isn't one right answer.
A few honest options, presented in no particular order:
Walk the connection from this entry outward.
- 1 CONDITION Restless legs syndrome (current)
The Knowledge Path is a curated walk. Every step is one decision away from the next.
You are here: Shrinkopedia, the concept layer of The Shrink Network.
Understand the idea here first, then follow it to the property that takes it further.
Read a related condition →Want to understand more first?
- Understand anxiety at AnxietyResource →
- Work with the pattern at shrinQ →
- Consider clinical evaluation at shrinkMD →
Disclosure: shrinkMD is the clinical care practice within The Shrink Network, the same network that publishes Shrinkopedia. Shrinkopedia takes no referral or affiliate commission for care.